Get notified when TNXP files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: TNXP Tonix Pharmaceuticals Holding Corp. 8-K

Tonix shareholders authorize reverse stock split up to 1-for-250, approve equity plan

Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read

Key Changes

  • high

    Board granted authority to execute reverse stock splits at ratios between 1:2 and 1:250 within two years, with full discretion on timing. Often used to maintain exchange listing requirements when share price falls too low.

  • medium

    Shareholders approved 2026 Stock Incentive Plan, creating new pool of shares for employee and director compensation. Vote was closer than other proposals (2.0M for vs 1.6M against), indicating some shareholder concern about dilution.

  • low

    Annual meeting achieved 54% quorum with all nine director nominees re-elected and PwC ratified as auditor for 2026. Routine governance matters with no contested votes.

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.

Partner

Trade TNXP commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify